IP Library Granted Patent US 10,206,895
Granted Patent B2
US 10,206,895 · App. 15/635,499 · Granted Feb 19, 2019

Sotalol compositions and uses of the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,206,895
App. No.
15/635,499
Granted
Feb 19, 2019
Kind
B2
Abstract

The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.

Claims (22)

1. An oral solution comprising sotalol hydrochloride, wherein the solution has an osmolality in the range of about 50 mOsm/kg to about 400 mOsm/kg.

2. The oral solution of claim 1 , wherein the solution is free of polymers.

3. The oral solution of claim 1 , wherein the solution has a pH between about 3 and about 7.

4. The oral solution of claim 1 , wherein the solution has an osmolality in the range of about 200 mOsm/kg to about 300 mOsm/kg.

5. The oral solution of claim 1 , wherein sotalol hydrochloride is present in an amount of about 5 mg/mL or about 0.5% by weight.

6. The oral solution of claim 1 , wherein the sotalol hydrochloride is present in an amount from about 0.2% to about 0.8% by weight.

7. The oral solution of claim 1 , further comprising an excipient selected from the group consisting of buffering substances, preservatives, high potency sweeteners and flavoring agents, or combinations thereof.

8. The oral solution of claim 7 , wherein the buffering substance is sodium citrate or citric acid, alone or in combination.

9. The oral solution of claim 7 , wherein the preservative is sodium benzoate.

10. The oral solution of claim 7 , wherein the high potency sweetener is sucralose.

11. The oral solution of claim 7 , wherein the flavoring agent is artificial grape flavor.

12. The oral solution of claim 1 , further comprising water in an amount of about 95% to about 99% by weight.

13. A method of delaying recurrence of atrial fibrillation/atrial flutter in a host in need thereof, comprising administering an effective amount of an oral solution comprising sotalol hydrochloride, wherein the solution has an osmolality in the range of about 50 mOsm/kg to about 400 mOsm/kg.

14. A method of treating documented life-threatening ventricular arrhythmias in a host in need thereof, comprising administering an effective amount of an oral solution comprising sotalol hydrochloride, wherein the solution has an osmolality in the range of about 50 mOsm/kg to about 400 mOsm/kg.

15. The oral solution of claim 1 , wherein the solution is stored at a temperature between about 25° C. and about 40° C. and a relative humidity of between about 60% and about 75%.

16. The method of claim 13 wherein the oral solution is stored at a temperature between about 25° C. and about 40° C. and a relative humidity of between about 60% and about 75%.

17. The method of claim 13 , wherein a 80 mg daily dose of the oral solution is administered.

18. The method of claim 13 , wherein administration of the oral solution occurs once, twice or three times a day.

19. The method of claim 13 , wherein the oral solution comprises water in an amount of about 95% to about 99% by weight and sotalol hydrochloride in an amount from about 0.2% to about 8% by weight.

20. The method of claim 14 , wherein a 80 mg daily dose is administered.

21. The method of claim 14 , wherein administration occurs once, twice or three times a day.

22. The method of claim 14 , wherein the oral solution comprises water in an amount of about 95% to about 99% by weight and sotalol hydrochloride in an amount from about 0.2% to about 8% by weight.

Assignments (7)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2024
From: ARBOR PHARMACEUTICALS, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 066391/0695 →
SECURITY INTEREST Recorded Sep 20, 2021
From: ARBOR PHARMACEUTICALS, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057544/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2021
From: ARBOR PHARMACEUTICALS, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 057440/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2020
From: ARBOR PHARMACEUTICALS, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 053344/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2017
From: THOMAS, H. GREG; KIEL, JEFFREY S.
To: ARBOR PHARMACEUTICALS, INC.
Reel/Frame 043941/0590 →